Long non-coding RNA AOC4P suppresses hepatocellular carcinoma metastasis by enhancing vimentin degradation and inhibiting epithelial-mesenchymal transition

Oncotarget

Volumn 6, Issue 27, 2015, Pages 23342-23357

  Wang, Tong Hong ^a   Lin, Yong Shiang ^b   Chen, Ying ^a   Yeh, Chau Ting ^a   Huang, Yen lin ^b   Hsieh, Tsung Han ^a   Shieh, Tzong Ming ^c   Hsueh, Chuen ^a,b   Chen, Tse Ching ^a,b  

^a CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^b CHANG GUNG UNIVERSITY   (Taiwan)

^c CHINA MEDICAL UNIVERSITY   (Taiwan)

Author keywords

Epithelial mesenchymal transition (EMT); Hepatocellular carcinoma (HCC); Long non coding RNA (lncRNA); Metastasis

Indexed keywords

AMINE OXIDASE (FLAVIN CONTAINING); LONG UNTRANSLATED RNA; VIMENTIN; AMINE OXIDASE (COPPER CONTAINING); LONG NON-CODING RNA AOC4P, HUMAN; LONG NON-CODING RNA AOC4P, MOUSE;

ADULT; ADVANCED CANCER; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AOC4P GENE; ARTICLE; CANCER INHIBITION; CANCER PROGNOSIS; CANCER STAGING; CELL MIGRATION; CELL PROLIFERATION; COHORT ANALYSIS; CONTROLLED STUDY; DOWN REGULATION; EPITHELIAL MESENCHYMAL TRANSITION; FEMALE; GENE EXPRESSION; GENE FUNCTION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; MOUSE; NONHUMAN; PROTEIN BINDING; PROTEIN DEGRADATION; PSEUDOGENE; TUMOR INVASION; AGED; ANIMAL; APOPTOSIS; BAGG ALBINO MOUSE; CELL DIFFERENTIATION; CELL MOTION; DISEASE COURSE; DISEASE FREE SURVIVAL; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETICS; LIVER TUMOR; METABOLISM; MIDDLE AGED; PROGNOSIS; PROPORTIONAL HAZARDS MODEL;

AGED; AMINE OXIDASE (COPPER-CONTAINING); ANIMALS; APOPTOSIS; CARCINOMA, HEPATOCELLULAR; CELL DIFFERENTIATION; CELL MOVEMENT; CELL PROLIFERATION; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; DOWN-REGULATION; EPITHELIAL-MESENCHYMAL TRANSITION; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LIVER NEOPLASMS; MALE; MICE; MICE, INBRED BALB C; MIDDLE AGED; NEOPLASM INVASIVENESS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PSEUDOGENES; RNA, LONG NONCODING; VIMENTIN;

EID: 84943414437     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.4344     Document Type: Article

References (43)

1. Hu DJ, Xing J, Tohme RA, Liao Y, Pollack H, Ward JW, Holmberg SD. Hepatitis B testing and access to care among racial and ethnic minorities in selected communities across the United States, 2009-2010. Hepatology. 2013;58:856-862.
2. Llovet JM. Liver cancer:time to evolve trial design after everolimus failure. Nature reviews Clinical oncology. 2014;11:506-507.
3. Lafaro KJ, Demirjian AN, Pawlik TM. Epidemiology of Hepatocellular Carcinoma. Surgical oncology clinics of North America. 2015;24:1-17.
4. Worns MA, Galle PR. HCC therapies-lessons learned. Nature reviews Gastroenterology & hepatology. 2014;11:447-452.
5. Cech TR, Steitz JA. The noncoding RNA revolutiontrashing old rules to forge new ones. Cell. 2014; 157:77-94.
6. Deng G, Sui G. Noncoding RNA in oncogenesis:a new era of identifying key players. International journal of molecular sciences. 2013;14:18319-18349.
7. Ling H, Fabbri M, Calin GA. MicroRNAs and other noncoding RNAs as targets for anticancer drug development. Nature reviews Drug discovery. 2013;12:847-865.
8. Jiang J, Gusev Y, Aderca I, Mettler TA, Nagorney DM, Brackett DJ, Roberts LR, Schmittgen TD. Association of MicroRNA expression in hepatocellular carcinomas with hepatitis infection, cirrhosis, and patient survival. Clinical cancer research:an official journal of the American Association for Cancer Research. 2008;14:419-427.
9. Park JK, Kogure T, Nuovo GJ, Jiang J, He L, Kim JH, Phelps MA, Papenfuss TL, Croce CM, Patel T, Schmittgen TD. miR-221 silencing blocks hepatocellular carcinoma and promotes survival. Cancer research. 2011; 71:7608-7616.
10. Koberle V, Kronenberger B, Pleli T, Trojan J, Imelmann E, Peveling-Oberhag J, Welker MW, Elhendawy M, Zeuzem S, Piiper A, Waidmann O. Serum microRNA-1 and microRNA-122 are prognostic markers in patients with hepatocellular carcinoma. European Journal of Cancer. 2013;49:3442-3449.
11. Giordano S, Columbano A. MicroRNAs:new tools for diagnosis, prognosis, and therapy in hepatocellular carcinoma? Hepatology. 2013;57:840-847.
12. Di Gesualdo F, Capaccioli S, Lulli M. A pathophysiological view of the long non-coding RNA world. Oncotarget. 2014;5:10976-10996.
13. Liu Y, Pan S, Liu L, Zhai X, Liu J, Wen J, Zhang Y, Chen J, Shen H, Hu Z. A genetic variant in long non-coding RNA HULC contributes to risk of HBV-related hepatocellular carcinoma in a Chinese population. PloS one. 2012; 7:e35145.
14. Batista PJ, Chang HY. Long noncoding RNAs:cellular address codes in development and disease. Cell. 2013; 152:1298-1307.
15. Schonrock N, Harvey RP, Mattick JS. Long noncoding RNAs in cardiac development and pathophysiology. Circulation research. 2012;111:1349-1362.
16. Tan L, Yu JT, Hu N, Tan L. Non-coding RNAs in Alzheimer's disease. Molecular neurobiology. 2013; 47:382-393.
17. Faghihi MA, Modarresi F, Khalil AM, Wood DE, Sahagan BG, Morgan TE, Finch CE, St Laurent G 3rd, Kenny PJ, Wahlestedt C. Expression of a noncoding RNA is elevated in Alzheimer's disease and drives rapid feedforward regulation of beta-secretase. Nature medicine. 2008;14:723-730.
18. He Y, Meng XM, Huang C, Wu BM, Zhang L, Lv XW, Li J. Long noncoding RNAs:Novel insights into hepatocelluar carcinoma. Cancer letters. 2014; 344:20-27.
19. Fang XY, Pan HF, Leng RX, Ye DQ. Long noncoding RNAs:Novel insights into gastric cancer. Cancer letters. 2015;356:357-366.
20. Lai MC, Yang Z, Zhou L, Zhu QQ, Xie HY, Zhang F, Wu LM, Chen LM, Zheng SS. Long non-coding RNA MALAT-1 overexpression predicts tumor recurrence of hepatocellular carcinoma after liver transplantation. Medical oncology. 2012;29:1810-1816.
21. Xu C, Yang M, Tian J, Wang X, Li Z. MALAT-1:a long non-coding RNA and its important 3' end functional motif in colorectal cancer metastasis. International journal of oncology. 2011;39:169-175.
22. Tano K, Mizuno R, Okada T, Rakwal R, Shibato J, Masuo Y, Ijiri K, Akimitsu N. MALAT-1 enhances cell motility of lung adenocarcinoma cells by influencing the expression of motility-related genes. FEBS letters. 2010; 584:4575-4580.
23. Ji P, Diederichs S, Wang W, Boing S, Metzger R, Schneider PM, Tidow N, Brandt B, Buerger H, Bulk E, Thomas M, Berdel WE, Serve H, Muller-Tidow C. MALAT-1, a novel noncoding RNA, and thymosin beta4 predict metastasis and survival in early-stage non-small cell lung cancer. Oncogene. 2003;22:8031-8041.
24. Ren S, Liu Y, Xu W, Sun Y, Lu J, Wang F, Wei M, Shen J, Hou J, Gao X, Xu C, Huang J, Zhao Y, Sun Y. Long Noncoding RNA MALAT-1 is a New Potential Therapeutic Target for Castration Resistant Prostate Cancer. The Journal of urology. 2013;190:2278-2287.
25. Kogo R, Shimamura T, Mimori K, Kawahara K, Imoto S, Sudo T, Tanaka F, Shibata K, Suzuki A, Komune S, Miyano S, Mori M. Long noncoding RNA HOTAIR regulates polycomb-dependent chromatin modification and is associated with poor prognosis in colorectal cancers. Cancer research. 2011;71:6320-6326.
26. Gupta RA, Shah N, Wang KC, Kim J, Horlings HM, Wong DJ, Tsai MC, Hung T, Argani P, Rinn JL, Wang Y, Brzoska P, Kong B, Li R, West RB, van de Vijver MJ, et al. Long non-coding RNA HOTAIR reprograms chromatin state to promote cancer metastasis. Nature. 2010;464:1071-1076.
27. Zhang JX, Han L, Bao ZS, Wang YY, Chen LY, Yan W, Yu SZ, Pu PY, Liu N, You YP, Jiang T. Kang CS and for the Chinese Glioma Cooperative G. HOTAIR, a cell cycle-associated long noncoding RNA and a strong predictor of survival, is preferentially expressed in classical and mesenchymal glioma. Neuro-oncology. 2013.
28. Cai B, Song XQ, Cai JP, Zhang S. HOTAIR:a cancerrelated long non-coding RNA. Neoplasma. 2014; 61:379-391.
29. Ge X, Chen Y, Liao X, Liu D, Li F, Ruan H, Jia W. Overexpression of long noncoding RNA PCAT-1 is a novel biomarker of poor prognosis in patients with colorectal cancer. Medical oncology. 2013;30:588.
30. Ferreira LB, Palumbo A, de Mello KD, Sternberg C, Caetano MS, de Oliveira FL, Neves AF, Nasciutti LE, Goulart LR, Gimba ER. PCA3 noncoding RNA is involved in the control of prostate-cancer cell survival and modulates androgen receptor signaling. BMC cancer. 2012;12:507.
31. Prensner JR, Iyer MK, Sahu A, Asangani IA, Cao Q, Patel L, Vergara IA, Davicioni E, Erho N, Ghadessi M, Jenkins RB, Triche TJ, Malik R, Bedenis R, McGregor N, Ma T, et al. The long noncoding RNA SChLAP1 promotes aggressive prostate cancer and antagonizes the SWI/SNF complex. Nature genetics. 2013;45:1392-1398.
32. Chen X, Lingala S, Khoobyari S, Nolta J, Zern MA, Wu J. Epithelial mesenchymal transition and hedgehog signaling activation are associated with chemoresistance and invasion of hepatoma subpopulations. Journal of hepatology. 2011; 55:838-845.
33. Park MY, Kim KR, Park HS, Park BH, Choi HN, Jang KY, Chung MJ, Kang MJ, Lee DG, Moon WS. Expression of the serum response factor in hepatocellular carcinoma: implications for epithelial-mesenchymal transition. International journal of oncology. 2007;31:1309-1315.
34. Shi X, Sun M, Liu H, Yao Y, Song Y. Long non-coding RNAs:a new frontier in the study of human diseases. Cancer letters. 2013;339:159-166.
35. Prensner JR, Chinnaiyan AM. The emergence of lncRNAs in cancer biology. Cancer discovery. 2011;1:391-407.
36. Singh RP, Raina K, Sharma G, Agarwal R. Silibinin inhibits established prostate tumor growth, progression, invasion, and metastasis and suppresses tumor angiogenesis and epithelial-mesenchymal transition in transgenic adenocarcinoma of the mouse prostate model mice. Clinical cancer research:an official journal of the American Association for Cancer Research. 2008;14:7773-7780.
37. Ting HJ, Deep G, Jain AK, Cimic A, Sirintrapun J, Romero LM, Cramer SD, Agarwal C, Agarwal R. Silibinin prevents prostate cancer cell-mediated differentiation of naive fibroblasts into cancer-associated fibroblast phenotype by targeting TGF beta2. Molecular carcinogenesis. 2014.
38. Lee J, Hahm ER, Marcus AI, Singh SV. Withaferin A inhibits experimental epithelial-mesenchymal transition in MCF-10A cells and suppresses vimentin protein level in vivo in breast tumors. Molecular carcinogenesis. 2015;54:417-29.
39. Thaiparambil JT, Bender L, Ganesh T, Kline E, Patel P, Liu Y, Tighiouart M, Vertino PM, Harvey RD, Garcia A, Marcus AI. Withaferin A inhibits breast cancer invasion and metastasis at sub-cytotoxic doses by inducing vimentin disassembly and serine 56 phosphorylation. International journal of cancer Journal international du cancer. 2011; 129:2744-2755.
40. Yang L, Froberg JE, Lee JT. Long noncoding RNAs:fresh perspectives into the RNA world. Trends in biochemical sciences. 2014;39:35-43.
41. Huarte M, Guttman M, Feldser D, Garber M, Koziol MJ, Kenzelmann-Broz D, Khalil AM, Zuk O, Amit I, Rabani M, Attardi LD, Regev A, Lander ES, Jacks T, Rinn JL. A large intergenic noncoding RNA induced by p53 mediates global gene repression in the p53 response. Cell. 2010; 142:409-419.
42. Braconi C, Kogure T, Valeri N, Huang N, Nuovo G, Costinean S, Negrini M, Miotto E, Croce CM, Patel T. microRNA-29 can regulate expression of the long noncoding RNA gene MEG3 in hepatocellular cancer. Oncogene. 2011;30:4750-4756.
43. Wang TH, Li WT, Yu SH, Au LC. The use of 10-23 DNAzyme to selectively destroy the allele of mRNA with a unique purine-pyrimidine dinucleotide. Oligonucleotides. 2008;18:295-299.